Henry Miller, a physician and molecular biologist, is the Robert Wesson Fellow in Scientific Philosophy and Public Policy at Stanford University’s Hoover Institution. He was the founding director of the Office of Biotechnology at the FDA.
One of the ways that scientists traditionally measure the well-being of a nation is to track the rate at which its citizens die, and how long they can be expected to live. So the news out of the National Center for Health Statistics earlier last month was disturbing: The overall U.S. death rate has increased for the first time in a decade, and that led to a drop in overall life expectancy for the first time since 1993.
The finding is thought to be due to a confluence of issues, including more obesity in the population, increasing long-term unemployment, more patients with chronic diseases, and a lack of breakthrough innovations to reduce the costs of care while increasing the quality of life. But the new data certainly highlight the critical need to provide better life-saving and life-prolonging therapies for patients.
While policymakers and stakeholders continue to debate how to solve these problems, there are some things that we know Congress can do to address them: enact smart, evidence-based policies, invest in private-public partnerships that enhance innovation, and eliminate roadblocks to America’s innovators.
The 21st Century Cures Act is an example of smart policies spurring solutions to the nation’s problems. This commonsense legislation, signed into law last month, is the result of years of negotiations, compromises, and passionate advocacy among countless stakeholders, including patient groups, health-care providers, hospitals, the life-science community, regulators, and more. Although not perfect, the legislation will boost research into some of the most vexing medical challenges our health-care system faces, while making sure that there are expedited pathways coupled with new resources for medical innovators and regulators to get breakthrough therapies to patients without delay.
Many roadblocks limit our nation’s innovators and entrepreneurs, some of which could be removed rapidly by Congress, especially when there is already broad, bipartisan agreement to do so. Perhaps no better example of this would be the permanent repeal of the disastrous medical-device excise tax. This monstrosity, a provision of the Affordable Care Act, was a dark cloud over medical-technology innovation during the years it was in place and led to drastic cuts in R&D, job losses, and lost opportunities to improve patient care. Congress recognized how detrimental this policy was to innovation and suspended the tax for two years, but if nothing is done, it will resume in 2018. Fully repealing the medical-device tax once and for all — which has been spearheaded by Representative Erik Paulsen (R., Minn.) — is a commonsense approach that would remove a massive obstacle to improving patient outcomes and the creation of high-tech manufacturing jobs.